MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Pliant Therapeutics Inc

Cerrado

1.55 -5.49

Resumen

Variación precio

24h

Actual

Mínimo

1.55

Máximo

1.69

Métricas clave

By Trading Economics

Ingresos

13M

-43M

Margen de beneficio

-2,190.837

Empleados

171

EBITDA

17M

-42M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+70.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-13M

91M

Apertura anterior

7.04

Cierre anterior

1.55

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Pliant Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct 2025, 17:05 UTC

Principales Movimientos del Mercado

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17 oct 2025, 15:03 UTC

Principales Movimientos del Mercado

Obook Shares Sink Following Public Debut

17 oct 2025, 14:41 UTC

Principales Movimientos del Mercado

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 20:34 UTC

Charlas de Mercado

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct 2025, 20:27 UTC

Charlas de Mercado

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct 2025, 19:46 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct 2025, 19:45 UTC

Charlas de Mercado

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct 2025, 18:45 UTC

Charlas de Mercado

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct 2025, 17:44 UTC

Charlas de Mercado

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 16:14 UTC

Charlas de Mercado

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct 2025, 16:04 UTC

Charlas de Mercado

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct 2025, 15:58 UTC

Charlas de Mercado

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct 2025, 15:56 UTC

Ganancias

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct 2025, 15:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 15:43 UTC

Charlas de Mercado

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17 oct 2025, 14:58 UTC

Charlas de Mercado

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17 oct 2025, 14:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 14:35 UTC

Charlas de Mercado
Ganancias

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

70.7% repunte

Estimación a 12 meses

Media 2.68 USD  70.7%

Máximo 4 USD

Mínimo 1.7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

1

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat